New treatment hope for rare kidney disease patients
NCT ID NCT04729062
Summary
This program provides early access to pegcetacoplan for people with rare kidney diseases called C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). The treatment is for patients aged 12 and older who have active kidney disease and haven't responded well to other available treatments. Participants will self-administer the medication or have a caregiver help with administration.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for C3 GLOMERULOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.